Long-term efficacy of low density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia

被引:229
作者
Mabuchi, H
Koizumi, J
Shimizu, M
Kajinami, K
Miyamoto, S
Ueda, K
Takegoshi, T
机构
[1] Kanazawa Univ, Sch Med, Dept Internal Med 2, Kanazawa, Ishikawa 9208641, Japan
[2] Himi Municipal Hosp, Dept Internal Med, Himi, Japan
[3] Komatsu Municipal Hosp, Dept Internal Med, Komatsu, Japan
[4] Fukui Prefectural Hosp, Dept Internal Med, Fukui, Japan
关键词
D O I
10.1016/S0002-9149(98)00692-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Familial hypercholesterolemia (FH) is characterized by severe hypercholesterolemia and premature coronary heart disease (CHD). The lower the plasma cholesterol level, the more likely it is that CHD can be prevented or retarded; aggressive cholesterol-lowering therapies may be indicated for FH patients with CHD. This study describes the long-term (6 years) safety and efficacy of intensive cholesterol-lowering therapies with low-density lipoprotein (LDL) apheresis in heterozygous FH patients with CHD. One hundred thirty heterozygous FH patients with CHD documented by coronary angiography had been treated by cholesterol-lowering drug therapy alone (n = 87) or LDL apheresis combined with cholesterol-lowering drugs (n = 43). Serum lipid levels and outcomes in each treatment group were compared after approximately 6 years. Both treatment groups had significant reductions in serum cholesterol, LDL cholesterol, and high density lipoprotein cholesterol levels. LDL apheresis significantly reduced LDL cholesterol levels from 7.42 +/- 1.73 to 3.13 +/- 0.80 mmol/L (58%) compared with group taking drug therapy, from 6.03 +/- 1.32 to 4.32 +/- 1.53 mmol/L (28%). With Kaplan-Meier analyses of the coronary events including nonfatal myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, and death from CHD, the rate of total coronary events was 72% lower in the LDL-apheresis group (10%) than in drug therapy group (36%) (p = 0.0088). It is concluded that LDL-apheresis is effective as treatment of CHD in FH heterozygotes, and may become the therapy of choice in severe types of FH. (C) 1998 by Excerpta Medico, Inc.
引用
收藏
页码:1489 / 1495
页数:7
相关论文
共 21 条
[1]  
ALLAIN CC, 1974, CLIN CHEM, V20, P470
[2]  
[Anonymous], 1995, FAMILIAL HYPERCHOLES
[3]   REGRESSION OF CAROTID PLAQUES DURING LOW-DENSITY-LIPOPROTEIN CHOLESTEROL ELIMINATION [J].
HENNERICI, M ;
KLEOPHAS, W ;
GRIES, FA .
STROKE, 1991, 22 (08) :989-992
[4]  
IGARASHI K, 1995, CIRCULATION S1, V92, P452
[5]  
KAJIKAWA T, 1981, J JPN ATHEROSCLER SO, V9, P393
[6]   REDUCTION OF LIPOPROTEIN(A) BY LDL-APHERESIS USING A DEXTRAN SULFATE CELLULOSE COLUMN IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA [J].
KOIZUMI, J ;
KOIZUMI, I ;
UNO, Y ;
INAZU, A ;
KAJINAMI, K ;
HARAKI, T ;
YAGI, K ;
KAMON, N ;
MIYAMOTO, S ;
TAKEGOSHI, T ;
MABUCHI, H ;
TAKEDA, R ;
TANI, N ;
TAKADA, S .
ATHEROSCLEROSIS, 1993, 100 (01) :65-74
[7]   LDL-apheresis atherosclerosis regression study (LAARS) - Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis [J].
Kroon, AA ;
Aengevaeren, WRM ;
vanderWerf, T ;
Uijen, GJH ;
Reiber, JHC ;
Bruschke, AVG ;
Stalenhoef, AFH .
CIRCULATION, 1996, 93 (10) :1826-1835
[8]   DISCRIMINATION OF FAMILIAL HYPERCHOLESTEROLEMIA AND SECONDARY HYPERCHOLESTEROLEMIA BY ACHILLES-TENDON THICKNESS [J].
MABUCHI, H ;
ITO, S ;
HABA, T ;
UEDA, K ;
UEDA, R ;
TATAMI, R ;
KAMETANI, T ;
KOIZUMI, J ;
OHTA, M ;
MIYAMOTO, S ;
TAKEDA, R ;
TAKEGOSHI, T .
ATHEROSCLEROSIS, 1977, 28 (01) :61-67
[9]   DEVELOPMENT OF CORONARY HEART-DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA [J].
MABUCHI, H ;
KOIZUMI, J ;
SHIMIZU, M ;
TAKEDA, R .
CIRCULATION, 1989, 79 (02) :225-332
[10]   EFFECTS OF CS-514 (EPTASTATIN), AN INHIBITOR OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME-A (HMG-COA) REDUCTASE, ON SERUM-LIPID AND APOLIPOPROTEIN LEVELS IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIC PATIENTS TREATED BY LOW-DENSITY LIPOPROTEIN (LDL)-APHERESISE [J].
MABUCHI, H ;
FUJITA, H ;
MICHISHITA, I ;
TAKEDA, M ;
KAJINAMI, K ;
KOIZUMI, J ;
TAKEDA, R ;
TAKEGOSHI, T ;
WAKASUGI, T ;
UEDA, K ;
MIYAMOTO, S ;
WATANABE, A ;
OOTA, M .
ATHEROSCLEROSIS, 1988, 72 (2-3) :183-188